Antipsychotic-induced extrapyramidal symptoms and their management

Praveen Dalaya, Kelvin L. Chou

Research output: Contribution to journalReview article

  • 41 Citations

Abstract

Background: Antipsychotic drugs have revolutionized the management of psychosis. Unfortunately, these drugs may cause a variety of distressing acute and delayed movement disorders, collectively known as 'extrapyramidal symptoms' (EPS). Objective: This review summarizes the current knowledge of the phenomenology, epidemiology, and pathophysiology of EPS, while highlighting their prevention and management. Methods: The review is limited to movement disorders resulting from typical and atypical antipsychotics. Recent and higher-quality evidence is emphasized. Conclusion: The pathophysiology of these disorders is still unclear. The use of atypical antipsychotics may have reduced EPS but has far from eliminated them. Available treatment options are often disappointing, especially for akathisia and the tardive syndromes. Future work will identify better treatments for these symptoms, as well as new antipsychotic agents that do not cause EPS.

LanguageEnglish (US)
Pages1451-1462
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number9
DOIs
StatePublished - Jun 1 2008

Fingerprint

Antipsychotic Agents
Movement Disorders
Drug-Induced Akathisia
Psychotic Disorders
Epidemiology
Therapeutics
Pharmaceutical Preparations

Keywords

  • Akathisia
  • Amantadine
  • Anticholinergic
  • Antipsychotic
  • Basal ganglia
  • Clozapine
  • Dopamine
  • Dyskinesia
  • Dystonia
  • Extrapyramidal
  • Haloperidol
  • Movement disorder
  • Neuroleptic
  • Parkinsonism
  • Prevention
  • Propranolol
  • Psychosis
  • Quetiapine
  • Receptor
  • Schizophrenia
  • Side effects
  • Tardive
  • Tetrabenazine
  • Treatment
  • Vitamin E

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Antipsychotic-induced extrapyramidal symptoms and their management. / Dalaya, Praveen; Chou, Kelvin L.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 9, 01.06.2008, p. 1451-1462.

Research output: Contribution to journalReview article

@article{55bf26a9809a4c6e955328a8d18555f0,
title = "Antipsychotic-induced extrapyramidal symptoms and their management",
abstract = "Background: Antipsychotic drugs have revolutionized the management of psychosis. Unfortunately, these drugs may cause a variety of distressing acute and delayed movement disorders, collectively known as 'extrapyramidal symptoms' (EPS). Objective: This review summarizes the current knowledge of the phenomenology, epidemiology, and pathophysiology of EPS, while highlighting their prevention and management. Methods: The review is limited to movement disorders resulting from typical and atypical antipsychotics. Recent and higher-quality evidence is emphasized. Conclusion: The pathophysiology of these disorders is still unclear. The use of atypical antipsychotics may have reduced EPS but has far from eliminated them. Available treatment options are often disappointing, especially for akathisia and the tardive syndromes. Future work will identify better treatments for these symptoms, as well as new antipsychotic agents that do not cause EPS.",
keywords = "Akathisia, Amantadine, Anticholinergic, Antipsychotic, Basal ganglia, Clozapine, Dopamine, Dyskinesia, Dystonia, Extrapyramidal, Haloperidol, Movement disorder, Neuroleptic, Parkinsonism, Prevention, Propranolol, Psychosis, Quetiapine, Receptor, Schizophrenia, Side effects, Tardive, Tetrabenazine, Treatment, Vitamin E",
author = "Praveen Dalaya and Chou, {Kelvin L.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1517/14656566.9.9.1451",
language = "English (US)",
volume = "9",
pages = "1451--1462",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Antipsychotic-induced extrapyramidal symptoms and their management

AU - Dalaya,Praveen

AU - Chou,Kelvin L.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background: Antipsychotic drugs have revolutionized the management of psychosis. Unfortunately, these drugs may cause a variety of distressing acute and delayed movement disorders, collectively known as 'extrapyramidal symptoms' (EPS). Objective: This review summarizes the current knowledge of the phenomenology, epidemiology, and pathophysiology of EPS, while highlighting their prevention and management. Methods: The review is limited to movement disorders resulting from typical and atypical antipsychotics. Recent and higher-quality evidence is emphasized. Conclusion: The pathophysiology of these disorders is still unclear. The use of atypical antipsychotics may have reduced EPS but has far from eliminated them. Available treatment options are often disappointing, especially for akathisia and the tardive syndromes. Future work will identify better treatments for these symptoms, as well as new antipsychotic agents that do not cause EPS.

AB - Background: Antipsychotic drugs have revolutionized the management of psychosis. Unfortunately, these drugs may cause a variety of distressing acute and delayed movement disorders, collectively known as 'extrapyramidal symptoms' (EPS). Objective: This review summarizes the current knowledge of the phenomenology, epidemiology, and pathophysiology of EPS, while highlighting their prevention and management. Methods: The review is limited to movement disorders resulting from typical and atypical antipsychotics. Recent and higher-quality evidence is emphasized. Conclusion: The pathophysiology of these disorders is still unclear. The use of atypical antipsychotics may have reduced EPS but has far from eliminated them. Available treatment options are often disappointing, especially for akathisia and the tardive syndromes. Future work will identify better treatments for these symptoms, as well as new antipsychotic agents that do not cause EPS.

KW - Akathisia

KW - Amantadine

KW - Anticholinergic

KW - Antipsychotic

KW - Basal ganglia

KW - Clozapine

KW - Dopamine

KW - Dyskinesia

KW - Dystonia

KW - Extrapyramidal

KW - Haloperidol

KW - Movement disorder

KW - Neuroleptic

KW - Parkinsonism

KW - Prevention

KW - Propranolol

KW - Psychosis

KW - Quetiapine

KW - Receptor

KW - Schizophrenia

KW - Side effects

KW - Tardive

KW - Tetrabenazine

KW - Treatment

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=46749102129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749102129&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.9.1451

DO - 10.1517/14656566.9.9.1451

M3 - Review article

VL - 9

SP - 1451

EP - 1462

JO - Expert Opinion on Pharmacotherapy

T2 - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -